Overview

Inventors of RECCE® 327 - a powerful new class of Broad Spectrum Antibiotics, synthesised to tackle the problem of antibiotic resistance (superbugs). Our lead drug candidate RECCE® 327 continues to undergo rigorous independent Safety and Efficacy testing, which continues to show no loss of activity, even with repeated use, against pathogenic Gram-positive and Gram-negative bacteria, including their superbug forms.

What Bacteria has RECCE antibiotics demonstrated capability against?

  • bacteria 1 1 Clostridium difficile
  • bacteria 2 2 Helicobacter pylori
  • bacteria3 Pseudomonas aeruginosa
  • bacteria 3 3 Neisseria gonorrhoeae
  • bacteria5 Escherichia coli
  • bacteria6 Klebsiella pneumoniae
  • bacteria9 Staphylococcus aureus
  • bacteria9 Streptococcus pyogenes
  • bacteria9 Enterococcus species

Designed with a purpose

RECCE® 327 is 100% water-soluble; wholly-synthetic compound; made up of millions of tiny monomers specially chosen for their desired characteristics; and, proprietarily bound together to form powerful polymers. It is our unique method of manufacturing that allows for the compound reproducibility of this, not cultivation of what’s found in nature. Commercial antibiotics are naturally derived; superbugs to them have been forming for millenniums and will continue to do so.

RECCE® 327 has been chemically engineered to be attracted to the unique ‘lipid’ outer-membranes of all bacteria, regardless of Gram stain, or mutation, breaking down the proteins in a non-specific way, causing the bacterial cell to burst. Any bacteria in the blood is bad bacteria and it is here that RECCE® 327 is designed to work.

While our main focus is the advancement of RECCE® 327 for sepsis, a number of other product candidates are under development, seeking to exploit the unique capabilities of RECCE® technologies across synergistic ‘urgent’ human health conditions.

product overview

Current RECCE® 327 development program

indication

INDICATION

discovery

DISCOVERY

pre clinical

PRE-CLINICAL

efficiancy

FIH SAFETY & EFFICACY*

regulatory

REGULATORY SUBMISSION**

SEPSIS (IV - S. AUREUS, E. COLI)
GASTRITIS (ORAL - H. PYLORI)
INTESTINAL (ORAL - E. COLI)

Estimated timelines/indications are subject to change in development plans and regulatory requirements/clarifications

FIH - First-in-human

*Testing for RECCE® antibiotic Safety and Efficacy

**Data submissions to regulators for permission to market

There have been no new classes of antibiotics on the market for over 30 years - Recce® 327 has the potential to break that mould. Recce® 327 is a synthetic polymer, designed to target bacteria that cause infectious disease – including ones that are resistant to current antibiotics – the superbugs. Bacterial infections of the blood are deadly and affect an estimated 30 million people world-wide every year - this is where Recce® 327 is designed to act. Recce® 327 is designed to be administered through injection so it can quickly spread through the blood stream.

Recce® 327 is designed to adhere to the outer cell wall of the infectious bacteria through hydrophobic interactions. This weakens the cell wall and internal pressures from within the cell cause the bacteria to burst. The body’s own mechanisms can then clear the infection. Normal non-bacterial cells remain intact as they do not contain high internal pressures.

Tests have shown Recce® 327 is fast acting and as a broad spectrum antibiotic is effective against gram positive and gram negative bacteria including antibiotic resistant superbugs. Following regulatory requirements for new antibiotics, safety and efficacy tests will continue to urgently explore Recce® 327’s ability to address the global threat posed by superbugs. Together we can make antibiotic resistance history – visit recce.com.au to find out more.

Sign up for news and updates

Receive news and information direct to your inbox.